Initial public offering (IPO) market activity picked up last week, with four traditional IPOs raising $266 million. The week ahead is expected to bring bigger listings, with Bausch & Lomb anticipated to raise near $1 billion in its debut.
In last week's largest debut, HillieVax, Inc. (NASDAQ: HLVX) raised $200 million after pricing shares at the midpoint. The biotech is in Phase 2 clinical trials for a novel norovirus vaccine, which is licensed from former parent company Takeda Pharma. The stock ended the week up 12%.
In last week's best performance, Tenon Medical, Inc. (NASDAQ: TNON) ended the week up 40% after raising $16 million after pricing shares at its midpoint. Surgical implant manufacturer is preparing for a national commercial launch of its proprietary surgical implant systems for sacroiliac joint fixation and fusion surgery.
Here's the rest of the week's listings in order of offering amount:
Belite Bio, Inc. (NASDAQ: BLTE) raised $36 million after pricing shares at its midpoint. The biotech is developing novel therapies for untreatable eye diseases related to retinal degeneration, as well as metabolic diseases. The company's lead candidate is being developed for autosomal recessive Stargardt disease. The stock ended the week down 23%.
Ostin Technology Group Co., Ltd. (NASDAQ: OST) raised $13.5 million after pricing its shares at $4 each. The Chinese supplier of display modules and polarizers popped 892% on its debut, the biggest IPO first day in about a year, before losing all of those gains by the end of the week. The stock finished the week down 67%.
For the week ahead:
Bausch & Lomb Corp. (NYSE: BLCO) plans to raise $966 million by pricing 35 million shares between $21 to $24 each. The spin-off of Bausch Health has a portfolio of over 400 consumer eye health product and has presence in about 100 countries. The company also plans to list on the Toronto Stock Exchange on the same day as its New York Stock Exchange debut.
PepGen, Inc. (NASDAQ: PEPG) plans to raise $101 million from 7.2 million shares priced between $13 to $15 each. The biotech is developing a pipeline of oligonucleotides for severe neuromuscular and neurological diseases using a platfrom orgicall created by researchers at the University of Oxford and the Medical Research Council of United Kingdom Research and Innovation. PepGen's lead candidate has entered Phase 1 trials for Duchenne muscular dystrophy, with topline data anticipated by the end of this year.